Clinical Trial

TR64 in Patients With Advanced Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a open-label, dose escalation, accelerated titration combined 3+3 design, phase I study, to evaluate the safety and tolerability, and to determine the RP2D of TR64 when administered qd in patients with advanced solid tumors. Up to 6 cohorts of 1-6 or 3-6 patients each will be treated in the study.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2022-12-05; most recent amendment 2024-05-13.
Status change: Not Yet Recruiting → Recruiting 2023-04-23
Trial Details
NCT Number NCT05649345
Lead Sponsor Tarapeutics Science Inc.
Conditions Advanced Solid Tumor
Enrollment 19 participants
Start Date 2023-01-12
Primary Completion 2026-08-30 (estimated)
Study Completion 2026-12-30 (estimated)
Updated on ClinicalTrials.gov 2024-05-14